Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 22 | 2017 | 546 | 1.630 |
Why?
|
| Platinum | 11 | 2014 | 19 | 1.140 |
Why?
|
| Acridines | 13 | 2014 | 19 | 1.120 |
Why?
|
| Deoxycytidine | 3 | 2017 | 63 | 0.640 |
Why?
|
| Organoplatinum Compounds | 5 | 2014 | 42 | 0.450 |
Why?
|
| Thiourea | 5 | 2015 | 5 | 0.440 |
Why?
|
| Neoplasms | 4 | 2019 | 610 | 0.430 |
Why?
|
| Nucleosides | 2 | 2016 | 10 | 0.400 |
Why?
|
| DNA | 7 | 2014 | 204 | 0.390 |
Why?
|
| Prodrugs | 2 | 2014 | 13 | 0.390 |
Why?
|
| Cell Line, Tumor | 17 | 2017 | 680 | 0.370 |
Why?
|
| Drug Design | 8 | 2014 | 44 | 0.370 |
Why?
|
| Intercalating Agents | 5 | 2014 | 8 | 0.370 |
Why?
|
| Lipids | 2 | 2016 | 209 | 0.360 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 87 | 0.340 |
Why?
|
| Drug Screening Assays, Antitumor | 12 | 2017 | 50 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 89 | 0.310 |
Why?
|
| Hyperthermia, Induced | 2 | 2007 | 235 | 0.300 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 10 | 0.290 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 15 | 0.290 |
Why?
|
| HL-60 Cells | 5 | 2008 | 14 | 0.290 |
Why?
|
| Sulfonamides | 1 | 2006 | 65 | 0.280 |
Why?
|
| DNA Damage | 4 | 2017 | 88 | 0.280 |
Why?
|
| Cytarabine | 2 | 2017 | 52 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 48 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 401 | 0.260 |
Why?
|
| Phosphatidic Acids | 1 | 2003 | 1 | 0.240 |
Why?
|
| Apoptosis | 4 | 2017 | 337 | 0.240 |
Why?
|
| Coordination Complexes | 2 | 2015 | 6 | 0.220 |
Why?
|
| Gold | 2 | 2015 | 15 | 0.220 |
Why?
|
| Humans | 30 | 2019 | 29093 | 0.220 |
Why?
|
| Anisomycin | 1 | 2002 | 4 | 0.210 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 12 | 0.210 |
Why?
|
| Mitoxantrone | 1 | 2002 | 17 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 37 | 0.210 |
Why?
|
| Structure-Activity Relationship | 10 | 2014 | 82 | 0.210 |
Why?
|
| DNA Adducts | 5 | 2014 | 13 | 0.200 |
Why?
|
| Urea | 3 | 2009 | 33 | 0.190 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 58 | 0.190 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 34 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2014 | 384 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2019 | 35 | 0.170 |
Why?
|
| Adenine | 2 | 2010 | 15 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2015 | 573 | 0.160 |
Why?
|
| Glycerophosphates | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 158 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 39 | 0.150 |
Why?
|
| Solubility | 3 | 2008 | 38 | 0.150 |
Why?
|
| Prodigiosin | 2 | 2006 | 2 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 77 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2014 | 69 | 0.120 |
Why?
|
| Cisplatin | 3 | 2012 | 69 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 35 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2015 | 23 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 62 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 92 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2013 | 48 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 45 | 0.110 |
Why?
|
| Carboxylic Acids | 1 | 2012 | 2 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 9 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 641 | 0.110 |
Why?
|
| Chelating Agents | 2 | 2009 | 17 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 4 | 2012 | 34 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2012 | 93 | 0.100 |
Why?
|
| Alkylating Agents | 1 | 2010 | 4 | 0.100 |
Why?
|
| Organogold Compounds | 1 | 2009 | 4 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 6 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 7 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2009 | 3 | 0.090 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2009 | 2 | 0.090 |
Why?
|
| Cell Line | 2 | 2015 | 449 | 0.080 |
Why?
|
| Animals | 6 | 2017 | 7297 | 0.080 |
Why?
|
| Guanidine | 1 | 2008 | 3 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 525 | 0.080 |
Why?
|
| Carboplatin | 1 | 2007 | 40 | 0.080 |
Why?
|
| Alkaloids | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2006 | 37 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 67 | 0.070 |
Why?
|
| Taxoids | 1 | 2006 | 47 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 50 | 0.070 |
Why?
|
| Deoxycytidine Kinase | 1 | 2005 | 2 | 0.070 |
Why?
|
| Phospholipids | 1 | 2005 | 26 | 0.070 |
Why?
|
| Monoterpenes | 1 | 2004 | 3 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2004 | 18 | 0.060 |
Why?
|
| Stereoisomerism | 3 | 2008 | 21 | 0.060 |
Why?
|
| Buffers | 1 | 2003 | 9 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Biological Availability | 2 | 2016 | 21 | 0.060 |
Why?
|
| Rhodium | 1 | 2002 | 1 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 2002 | 18 | 0.060 |
Why?
|
| Models, Molecular | 3 | 2008 | 178 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2002 | 11 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 13 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 18 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 44 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 36 | 0.050 |
Why?
|
| Cell Survival | 2 | 2013 | 272 | 0.050 |
Why?
|
| Pyridines | 1 | 2002 | 78 | 0.050 |
Why?
|
| Imidazoles | 1 | 2002 | 104 | 0.050 |
Why?
|
| Transfection | 1 | 2002 | 192 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2002 | 281 | 0.050 |
Why?
|
| Mice | 3 | 2014 | 2368 | 0.050 |
Why?
|
| Water | 2 | 2012 | 50 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2009 | 77 | 0.040 |
Why?
|
| Female | 4 | 2013 | 18164 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 4 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 60 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 76 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2017 | 37 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2017 | 55 | 0.040 |
Why?
|
| Random Allocation | 1 | 2017 | 213 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 249 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2008 | 53 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2019 | 666 | 0.030 |
Why?
|
| Photochemistry | 2 | 2006 | 5 | 0.030 |
Why?
|
| Quinazolines | 1 | 2015 | 31 | 0.030 |
Why?
|
| G-Quadruplexes | 1 | 2014 | 8 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2014 | 14 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 711 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 38 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 93 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 171 | 0.030 |
Why?
|
| Hydrazines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 142 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 89 | 0.030 |
Why?
|
| Esters | 1 | 2012 | 9 | 0.030 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2012 | 15 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 301 | 0.030 |
Why?
|
| DNA Cleavage | 1 | 2010 | 4 | 0.020 |
Why?
|
| Netropsin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vero Cells | 1 | 2009 | 3 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2009 | 17 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 81 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 11 | 0.020 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 30 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2008 | 30 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 46 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 276 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 23 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 64 | 0.020 |
Why?
|
| Sulfur Compounds | 1 | 2006 | 6 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 666 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 240 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2006 | 18 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 350 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 436 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 250 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 9 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2004 | 23 | 0.020 |
Why?
|
| Caspases | 1 | 2004 | 31 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2004 | 30 | 0.020 |
Why?
|
| Genes, ras | 1 | 2004 | 26 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 74 | 0.020 |
Why?
|
| Cell Division | 1 | 2004 | 97 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2004 | 126 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 155 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 143 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 2001 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 183 | 0.010 |
Why?
|
| Chemistry | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 2002 | 2 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 100 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 80 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 249 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 82 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 7 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 466 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 10829 | 0.010 |
Why?
|